Systematic Review of the Approach towards Vaccination and Available Treatment for COVID-19 with Special Reference to India

P. Gware, P. Rajput
{"title":"Systematic Review of the Approach towards Vaccination and Available Treatment for COVID-19 with Special Reference to India","authors":"P. Gware, P. Rajput","doi":"10.35248/2161-0517.20.09.188","DOIUrl":null,"url":null,"abstract":"An intense respiratory ailment, brought about by a novel coronavirus (SARS-CoV-2, recently known as 2019-nCoV), the coronavirus sickness 2019 (COVID-19) has spread all through China and got overall consideration. On 30 January 2020, World Health Organisation (WHO) formally proclaimed the COVID-19 pestilence as a general wellbeing crisis of global concern. The rise of SARS-CoV-2, since the serious intense respiratory disorder coronavirus (SARS-CoV) in 2002 and Middle East respiratory disorder coronavirus (MERS-CoV) in 2012, denoted the third presentation of a profoundly pathogenic and enormous scope plague coronavirus into the human populace in the twenty-first century. Starting at 1 March 2020, a sum of 87,137 affirmed cases universally, 79,968 affirmed in China and 7169 outside of China, with 2977 passings (3.4%) had been accounted for by WHO. In the interim, a few autonomous research bunches have recognized that SARS-CoV-2 has a place with β-coronavirus, with exceptionally indistinguishable genome to bat coronavirus, highlighting bat as the characteristic host. The epic coronavirus utilizes a similar receptor, angiotensin-changing over compound 2 (ACE2) as that for SARS-CoV, and for the most part spreads through the respiratory tract. Critically, progressively proof demonstrated supported human-to-human transmission, alongside many sent out cases over the globe. The clinical side effects of COVID-19 patients incorporate fever, hack, weariness and a little populace of patients showed up gastrointestinal contamination side effects. The old and individuals with basic ailments are helpless to contamination and inclined to genuine results, which might be related with intense respiratory trouble disorder (ARDS) and cytokine storm. At present, there are scarcely any particular antiviral methodologies, however a few intense applicants of antivirals and repurposed drugs are under examination.","PeriodicalId":91631,"journal":{"name":"Virology & mycology : infectious diseases","volume":"9 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology & mycology : infectious diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2161-0517.20.09.188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

An intense respiratory ailment, brought about by a novel coronavirus (SARS-CoV-2, recently known as 2019-nCoV), the coronavirus sickness 2019 (COVID-19) has spread all through China and got overall consideration. On 30 January 2020, World Health Organisation (WHO) formally proclaimed the COVID-19 pestilence as a general wellbeing crisis of global concern. The rise of SARS-CoV-2, since the serious intense respiratory disorder coronavirus (SARS-CoV) in 2002 and Middle East respiratory disorder coronavirus (MERS-CoV) in 2012, denoted the third presentation of a profoundly pathogenic and enormous scope plague coronavirus into the human populace in the twenty-first century. Starting at 1 March 2020, a sum of 87,137 affirmed cases universally, 79,968 affirmed in China and 7169 outside of China, with 2977 passings (3.4%) had been accounted for by WHO. In the interim, a few autonomous research bunches have recognized that SARS-CoV-2 has a place with β-coronavirus, with exceptionally indistinguishable genome to bat coronavirus, highlighting bat as the characteristic host. The epic coronavirus utilizes a similar receptor, angiotensin-changing over compound 2 (ACE2) as that for SARS-CoV, and for the most part spreads through the respiratory tract. Critically, progressively proof demonstrated supported human-to-human transmission, alongside many sent out cases over the globe. The clinical side effects of COVID-19 patients incorporate fever, hack, weariness and a little populace of patients showed up gastrointestinal contamination side effects. The old and individuals with basic ailments are helpless to contamination and inclined to genuine results, which might be related with intense respiratory trouble disorder (ARDS) and cytokine storm. At present, there are scarcely any particular antiviral methodologies, however a few intense applicants of antivirals and repurposed drugs are under examination.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对COVID-19疫苗接种和可用治疗方法的系统评价,特别以印度为例
2019冠状病毒病(COVID-19)是一种由新型冠状病毒(SARS-CoV-2,最近被称为2019- ncov)引起的严重呼吸道疾病,已在中国蔓延并得到全面考虑。2020年1月30日,世界卫生组织(世卫组织)正式宣布2019冠状病毒病疫情为全球关注的一般性福祉危机。SARS-CoV-2的出现是继2002年的严重急性呼吸系统疾病冠状病毒(SARS-CoV)和2012年的中东呼吸系统疾病冠状病毒(MERS-CoV)之后,21世纪第三次出现致病性强、范围广的鼠疫冠状病毒。截至2020年3月1日,全球确诊病例87,137例,中国确诊病例79,968例,中国境外确诊病例7169例,世卫组织已确认2977例(3.4%)。在此期间,一些自主研究小组已经认识到SARS-CoV-2与β-冠状病毒有一定的关系,其基因组与蝙蝠冠状病毒异常难以区分,突出了蝙蝠是特征宿主。新型冠状病毒利用一种与sars冠状病毒相似的受体,即血管紧张素改变化合物2 (ACE2),并且在很大程度上通过呼吸道传播。至关重要的是,越来越多的证据支持人与人之间的传播,以及全球各地的许多病例。新冠肺炎患者的临床副作用包括发烧、乏力、疲倦,少数患者出现胃肠道污染副作用。老年人和有基础疾病的人对污染无能,倾向于真实的结果,这可能与严重的呼吸障碍(ARDS)和细胞因子风暴有关。目前,几乎没有任何特定的抗病毒方法,但一些抗病毒药物和重新用途药物的强烈申请正在审查中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Chronic Respiratory Diseases and Age at Menarche: A Short Communication Top Ten Viruses Reported on Chilly in Southeast Asia Possible Collaboration of Veterinarians and Medicos over the Fight against Covid-19 with andldquo;One-Health Approachandrdquo; Potential for Biological Control of Postharvest Fungal Rot of White Yam (Dioscorea rotundata Poir) Tubers in Storage with Trichoderma harzianum An Overview of Fungus Eye Infection
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1